Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.

The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASH 2022 | Expanding treatment options for AML to patients with MDS

David Sallman, MD, Moffitt Cancer Center, Tampa, FL, emphasizes the importance of including patients with myelodysplastic syndromes (MDS) in trials evaluating therapies for acute myeloid leukemia (AML), explaining that MDS cells express many of the targets utilized for AML therapies. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Takeda: Consultancy; Shattuck Labs: Membership on an entity’s Board of Directors or advisory committees; Kite: Membership on an entity’s Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Incyte: Speakers Bureau; Syndax: Membership on an entity’s Board of Directors or advisory committees; Magenta: Consultancy; Intellia: Membership on an entity’s Board of Directors or advisory committees; BMS: Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Aprea: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Agios: Membership on an entity’s Board of Directors or advisory committees; AbbVie: Membership on an entity’s Board of Directors or advisory committees; Syntrix Pharmaceuticals: Research Funding; Lixte: Patents & Royalties: LB-100; Nemucore: Membership on an entity’s Board of Directors or advisory committees